AbbVie

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

News

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

AbbVie's Immunogen buy delivers rare cancer drug approval

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

News

FDA declines to approve AbbVie's Botox follow-up

AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.

AbbVie climbs post-Allergan M&A peak with Apogee buy

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Immunogen buy delivers rare cancer drug approval

FDA declines to approve AbbVie's Botox follow-up

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks